GlassScriptPhysician profile
Eric B Blum
NPI 1447466289
$10,929.66
in general payments reported to CMS, 2019-2025
43 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,259 · 2020: $866 · 2021: $1,347 · 2022: $2,107 · 2023: $1,598 · 2024: $1,330 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,331 · Education: $19.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.27 |
| Education | $19.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,262.99 | 2019-2025 | Rinvoq, Linzess, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $1,386.85 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $944.73 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $938.86 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Pfizer INC. | $505.27 | 2019-2025 | |
| Celgene Corporation | $416.60 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $335.05 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $260.93 | 2021-2024 | Linzess |
| Genzyme Corporation | $244.50 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $239.92 | 2019-2023 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $237.18 | 2019-2023 | Ocaliva |
| Braintree Laboratories, INC. | $207.07 | 2019-2023 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $201.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $163.87 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $160.20 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.